NEWSFLASH! Spinraza PBS Listing Expansion

1 March 2024

Following the Pharmaceutical Benefits Advisory Committee (PBAC) positive recommendation in August 2023, we are thrilled to announce that today, the Pharmaceutical Benefits Scheme (PBS) has expanded its listing of Spinraza to include pre-symptomatic babies with three copies of the Survival of Motor Neuron 2 (SMN2) gene.

This is fantastic news, now providing families of these babies a second treatment option.